Capabilities

A commercialization platform
enabling precision diagnostics to scale.

Your existing diagnostics workflow runs the assay. Precision Suite helps bring it to market with ordering, reporting, client services, EHR and billing integrations. All from a system built for clinical compliance.

IndicationsOncologyCardiovascularNeurodegenerativeRare disease

Platform overview

Integrate existing workflows with clinical tools to deliver results to patients

Your LIMS and existing systems handle the proprietary science. Precision Suite adds the commercial layer that connects your results to your market: providers, clinicians, and patients.

Back to overview →

Lab environment

Existing LIMS
Sequencer / Analyzer

Precision Suite commercial layer

Dendi Precision Suite
EHR delivery
Provider Portal
Billing / RCM
Results Routing
CRM / Client Services

Full audit trail across all integrations · configurable per channel

Precision Diagnostics assays

Built for precision diagnostics across disease areas

The commercial infrastructure — ordering, reporting templates, EHR delivery, billing codes, and analytics — works across all indication types. Precision Suite is built to launch any structured assay output.

Oncology

Solid tumors, liquid biopsy, and hereditary cancer — with variant classification, TMB, MSI, and structured panel reporting.

NGS panelsTMB / MSIVariant classification

Cardiovascular

Genetic risk panels, biomarker assays, and inherited cardiomyopathy testing.

Lipid geneticsCardiomyopathyACS markers

Neurodegenerative

Early detection and progression biomarkers for Alzheimer's, Parkinson's, and ALS.

CSF biomarkerscfDNANfL testing

Rare disease

Whole-exome, gene panels, and functional genomic assays for rare and ultra-rare conditions.

WES / WGSIEIMetabolic disorders

Who this is for

Built for labs ready for go-to-market

Precision Suite is built for labs that develop their own tests and need commercial infrastructure to go to market.

Lab type

Precision medicine spinouts

Labs spun out of academic medical centers or research programs with validated assays and a pathway to LDT commercialization.

Need to build commercial ops from scratch without disrupting the R&D environment already in place.

Lab type

Biotech diagnostic divisions

Biotech companies that have developed a companion diagnostic or standalone molecular assay and need a lab commercialization layer.

Need provider ordering infrastructure and billing-ready reporting without a full LIS rebuild.

Lab type

Specialty reference labs

Reference labs adding novel precision assays alongside their existing menu, managed separately from established testing workflows.

Need to support a new assay's commercial launch without rebuilding their existing production LIS.

01 Clinical commercialization

Make your assay easy to order, track, and adopt.

Novel diagnostic assays face commercial challenges when ordering, tracking, and result delivery add friction for providers. Precision Suite gives your lab the operational infrastructure to support clinical adoption from day one — without rebuilding your diagnostics workflows.

  • Provider portal for direct order submission and result access
  • Fax and portal report distribution to ordering physicians
  • AOE tracking for specimen and accessioning numbers
  • Notification workflows and escalation routing for your ops team
Issues Module — Issues QueueStay organized with flexible tagging
Filtered by:Clinical reviewCS follow-up14 open
#4821
Chen, M.
Missing AOE — specimen ID
Clinical review
Dr. Reeves
#4809
Patel, R.
Provider portal delivery failed
CS follow-up
T. Walsh
#4817
Williams, J.
QC flag — lot #2941B
Clinical reviewQC hold
Dr. Reeves
#4823
Kim, S.
Insurance pre-auth pending
CS follow-up
T. Walsh
#4831
Garcia, L.
Fax delivery unconfirmed — retry
Resolved
T. Walsh
02 Custom precision diagnostic reporting

Turn your assay output into a report providers can act on.

Precision Suite receives structured result data from your diagnostics software and pipeline, then generates the clinical-grade reports your providers need — formatted for your assay, branded for your lab, and delivered through the channels they actually use.

  • Multiple custom report templates per assay type
  • Variant classification, TMB, MSI, and structured interpretation sections
  • Historical results and longitudinal trend data surfaced within the report
  • Full lab branding — logo, typography, and layout control
  • HL7, FHIR, and custom export for downstream EHR and registry delivery
See report examples
Williams, James A.
DOB: 1961-03-14 · Acc# 4817 · NGS Panel v2
Ordering: Dr. Chen · Cleveland Clinic Oncology
Final

Variant findings

Gene
Variant
VAF
Classification
Exon
KRAS
p.G12D
34.2%
Pathogenic
2
TP53
p.R175H
28.7%
Pathogenic
5
PIK3CA
p.E545K
12.1%
VUS
9

Interpretation

Two pathogenic variants identified in KRAS and TP53. KRAS G12D is associated with reduced response to anti-EGFR therapy. TMB: 8.4 mut/Mb (intermediate). MSI status: MSS. Clinical correlation recommended.
Mitchell, Robert W.
DOB: 1968-07-22 · Acc# 5102 · Lipid Genetics Panel v1
Ordering: Dr. Patel · UH Preventive Cardiology
Final

Variant findings

Gene
Variant
Zygosity
Classification
PCSK9
p.R46L
Heterozygous
Pathogenic
LDLR
p.D200N
Heterozygous
Likely pathogenic
APOB
p.R3527Q
Heterozygous
VUS

Interpretation

Findings consistent with familial hypercholesterolemia (FH). PCSK9 p.R46L is a known gain-of-function variant associated with significantly elevated LDL-C. LDLR p.D200N has been reported in FH cohorts. Genetic counseling and consideration of PCSK9 inhibitor therapy recommended. Cascade screening of first-degree relatives advised.
Anderson, Margaret E.
DOB: 1952-11-03 · Acc# 5287 · CSF Biomarker Panel v2
Ordering: Dr. Kim · Case Western Neurology
Final

CSF biomarker results

Marker
Result
Ref range
Status
Amyloid β42/40
0.048
>0.070
↓ Low
p-tau 217
186 pg/mL
<75 pg/mL
↑ High
NfL
1,240 pg/mL
<920 pg/mL
↑ Elevated
GFAP
482 pg/mL
<300 pg/mL
↑ Elevated

Interpretation

Biomarker profile is consistent with Alzheimer's disease pathology. Decreased Aβ42/40 ratio and markedly elevated p-tau 217 indicate amyloid burden and tau pathology. Elevated NfL and GFAP reflect ongoing neurodegeneration and neuroinflammation. Findings support an AD diagnosis in the appropriate clinical context. Correlation with imaging and clinical assessment recommended.
03 Integration with your existing stack

Connects to your diagnostics software. Routes to your business systems.

Precision Suite is designed to receive result data from your existing diagnostics environment — whatever systems and pipelines you already use — and route it to the commercial systems your business depends on. You don't rebuild. You connect.

  • Accepts result input from your existing LIMS and diagnostics pipeline via REST API or HL7
  • Bidirectional EHR connectivity via HL7 and FHIR
  • Instrument and sequencer connections for direct result ingestion
  • Billing system integration with CPT and ICD code mapping
  • Reference lab send-out and result routing
  • Custom export for CRM, commercial reporting, or any downstream consumer
HL7FHIRREST APIInstrument connectorsBilling integrationCustom export
View all integrations

Your diagnostics environment

Existing LIMS
Instruments & pipelines
Sequencer / analyzer
Dendi Precision Suite
EHR (HL7/FHIR)
Billing / RCM
Reference labs
Provider portal
CRM / commercial

Result routing & audit · configurable per channel

04 Compliance-ready infrastructure

A commercial system that meets clinical standards.

Your commercial-facing system carries the same compliance burden as your diagnostics operations. Payer relationships, enterprise procurement, and CAP/CLIA accreditation all require documented evidence of security, quality, and operational controls. Precision Suite is built for that environment.

CAP / CLIA
SOC 2 Type II
HIPAA
HL7 / FHIR
  • CAP / CLIA-aligned workflow templates and QC documentation
  • Per-sample QC with lot traceability and Levey-Jennings charts
  • Full audit trail across every order, result, and user action
  • SOC 2 Type II-aligned data practices and access controls
  • SSO integration and role-based permissions across all users
Review security documentation
Following the vacating of the FDA LDT rule in 2025, CAP/CLIA accreditation and internal quality systems remain the primary compliance framework for clinical assay labs.

CAP / CLIA-aligned workflows

Pre-configured QC and documentation designed to align with CAP checklist requirements for molecular and oncology labs.

Per-sample QC

Lot traceability, QC trending, and Levey-Jennings charts built into every assay workflow.

SOC 2 readiness

Data practices, access controls, and audit logging aligned with SOC 2 Type II requirements.

SSO & access controls

Role-based permissions, SSO integration, and per-user audit logs across all system activity.

05 Commercial visibility & analytics

One source of truth from order to result.

Commercial teams need to know which providers are ordering, where samples are getting stuck, and what's hurting adoption. Lab directors need TAT and QC data. Finance needs billing status. Precision Suite brings it together in a single operational view.

  • Provider and ordering activity dashboards
  • TAT analytics with per-assay and per-provider breakdowns
  • Historical result trends and QC trending over time
  • Issues queue with resolution tracking and escalation history
  • Custom export for commercial, ops, and finance reporting
See a demo dashboard

This month · June 2026

847
Active orders
97.2%
On-time TAT
134
Active providers
14
Open issues

Provider activity — top 5 this month

Provider
Orders
Avg TAT
vs prior
Status
Dr. Chen, Cleveland Clinic
84
3.2d
▲ 12%
Active
Dr. Patel, UH System
61
3.5d
▲ 8%
Active
Dr. Williams, MetroHealth
47
4.1d
▼ 3%
Active
Dr. Kim, Case Western
39
3.8d
▲ 21%
Active
Dr. Nguyen, Summa Health
18
5.2d
▼ 14%
Flagged

Time to market New

From integration to first commercial orders in 6 weeks.

Precision Suite is designed to go live alongside your diagnostics environment without a rebuild. Labs typically reach live ordering within 3–6 weeks of starting implementation.

Week 1–2

Integration scoping & API connection

Connect Precision Suite to your existing LIMS or diagnostics pipeline via REST API or HL7. Map your result data structure to the reporting schema. No code changes required on your side in most cases.

REST API / HL7 setupResult schema mappingBilling code configuration

Week 2–4

Report template build & provider portal setup

Build your custom report template — lab branding, interpretation sections, variant tables, or any structured result output. Configure the provider portal, initiate EHR interfaces, and test the ordering workflow end-to-end.

Custom report templatesProvider portal configEHR delivery routing

Week 4–6

QC workflow validation & compliance documentation

Validate QC workflows against your CAP/CLIA checklist. Run test orders through the full cycle. Generate compliance documentation for your internal quality system.

CAP/CLIA QC reviewEnd-to-end order testAudit trail validation

Week 6+

Live — first commercial orders

Go live with your first ordering providers. Your diagnostics environment continues unchanged; Precision Suite handles ordering, result delivery, and billing in parallel.

Provider onboardingLive TAT monitoringCommercial analytics

Timeline varies by integration complexity and whether EHR delivery is required at launch. Complex NGS pipeline integrations or multi-EHR setups typically run 6–10 weeks.

Ready to plan your launch?

Talk to the team about your assay and your timeline.

We scope every implementation around your existing diagnostics environment. Most labs start with a 30-minute technical review before kickoff.

1

Technical review — walk us through your current LIMS and pipeline setup.

2

Integration scoping — we confirm the API connection approach and data mapping requirements.

3

Timeline estimate — you get a specific go-live date, not a range.

Request a demo

Ready when you are

Your assay is ready. Let's build the commercial layer around it.

Talk to the team about your assay and your timeline.

Request a demo